Sergio Wittlin

Basel, BS 4002, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 136 publications

Antimalarial cytoskeletal targeting with broad apicomplexan activity.

Antimalarial cytoskeletal targeting with broad apicomplexan activity.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 24, 2026

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of PfArk1 and Hemozoin Formation.

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of PfArk1 and Hemozoin Formation.

Journal: ACS chemical biology

Published: June 13, 2026

Double Mutations in Plasmodium falciparum Kelch13 drive resistance to next-generation artemisinin derivatives in malaria parasites.

Double Mutations in Plasmodium falciparum Kelch13 drive resistance to next-generation artemisinin derivatives in malaria parasites.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Identification of Compound 15 (MMV1581361) as a PfATP4 Inhibitor with Transmission-Blocking Activity and In Vivo Efficacy in a SCID Mouse Model of Malaria.

Identification of Compound 15 (MMV1581361) as a PfATP4 Inhibitor with Transmission-Blocking Activity and In Vivo Efficacy in a SCID Mouse Model of Malaria.

Journal: Journal of medicinal chemistry

Published: February 11, 2026

Using Next Generation Chemiluminescent Probes to Improve the Plasmodium falciparum in vitro Parasite Reduction Ratio (PRR) Assay.

Using Next Generation Chemiluminescent Probes to Improve the Plasmodium falciparum in vitro Parasite Reduction Ratio (PRR) Assay.

Journal: ACS infectious diseases

Published: January 23, 2026

Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class.

Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class.

Journal: Malaria journal

Published: October 26, 2025

A Novel Class of Orally Bioavailable Phenylglycine-Benzoxaborole Conjugates with Antimalarial Activity and Potentially Novel Mechanism of Action.

A Novel Class of Orally Bioavailable Phenylglycine-Benzoxaborole Conjugates with Antimalarial Activity and Potentially Novel Mechanism of Action.

Journal: ACS medicinal chemistry letters

Published: September 15, 2025

Structure-Activity Relationships of 3-Hydroxypropanamidines (HPAs) with Potent In Vivo Antimalarial Activity.

Structure-Activity Relationships of 3-Hydroxypropanamidines (HPAs) with Potent In Vivo Antimalarial Activity.

Journal: Journal of medicinal chemistry

Published: September 08, 2025

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against Plasmodium falciparum via Dual Inhibition of PfArk1 and Hemozoin Formation.

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against Plasmodium falciparum via Dual Inhibition of PfArk1 and Hemozoin Formation.

Journal: bioRxiv : the preprint server for biology

Published: August 12, 2025

Medicinal Chemistry Progression of Sapanisertib, the Anticancer and Dual Plasmodium Phosphatidylinositol 4-Kinase Beta and cGMP-Dependent Protein Kinase Inhibitor, for Malaria.

Medicinal Chemistry Progression of Sapanisertib, the Anticancer and Dual Plasmodium Phosphatidylinositol 4-Kinase Beta and cGMP-Dependent Protein Kinase Inhibitor, for Malaria.

Journal: Journal of medicinal chemistry

Published: May 16, 2025

Cell-Based Progression of Spiroindoline Phenotypic Hits Leads to the Identification of Compounds with Diverging Parasitological Profiles against the Human Malaria Parasite Plasmodium falciparum.

Cell-Based Progression of Spiroindoline Phenotypic Hits Leads to the Identification of Compounds with Diverging Parasitological Profiles against the Human Malaria Parasite Plasmodium falciparum.

Journal: Journal of medicinal chemistry

Published: May 12, 2025

TKK130 is a 3-Hydroxy-Propanamidine (HPA) with Potent Antimalarial In Vivo Activity and a High Barrier to Resistance.

TKK130 is a 3-Hydroxy-Propanamidine (HPA) with Potent Antimalarial In Vivo Activity and a High Barrier to Resistance.

Journal: Journal of medicinal chemistry

Published: December 26, 2024

Showing 1-12 of 136

Last Updated: 09/26/2026